A5055329132- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Cytokine Signaling Pathways and Interactions
- Viral Infections and Immunology Research
- Immunotherapy and Immune Responses
- Full-Duplex Wireless Communications
- Plant Virus Research Studies
- Systemic Lupus Erythematosus Research
- Infectious Encephalopathies and Encephalitis
- Systemic Sclerosis and Related Diseases
- Monoclonal and Polyclonal Antibodies Research
- Immune Response and Inflammation
- Chronic Myeloid Leukemia Treatments
- Sphingolipid Metabolism and Signaling
- Cerebral Venous Sinus Thrombosis
- Acute Lymphoblastic Leukemia research
- Glioma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Neurogenesis and neuroplasticity mechanisms
- Fibromyalgia and Chronic Fatigue Syndrome Research
- RNA Interference and Gene Delivery
- Thermal Regulation in Medicine
- Vestibular and auditory disorders
- T-cell and B-cell Immunology
Amsterdam Neuroscience
2008-2025
Amsterdam University Medical Centers
2019-2025
Vrije Universiteit Amsterdam
1999-2025
Amsterdam UMC Location Vrije Universiteit Amsterdam
2009-2024
Sanquin
2017-2020
University College London
1997-2020
St. Antonius Ziekenhuis
2020
Medizinische Hochschule Hannover
2020
Rijnstate Hospital
2020
University of Amsterdam
1995-2020
There is evidence that treatment with an antibody to tumor necrosis factor alpha (TNF alpha) improves animal model of multiple sclerosis (MS) and beneficial in two systemic inflammatory disease humans, but there are no reports about anti-TNF MS. Therefore, we treated rapidly progressive MS patients intravenous infusions a humanized mouse monoclonal (cA2) open-label phase I safety trial monitored their clinical status, gadolinium-enhanced brain magnetic resonance imaging (MRI), peripheral...
MRI findings are increasingly used as outcome measures in therapeutic trials MS. The discrepancy between the extent of lesions on conventional T2 images and clinical condition patient is one problems encountered such studies. This clinical-radiological paradox prevents use data surrogate markers disability A recent pilot study suggested a relationship hypointense T1 disability. To assess more detail correlation changes lesion load T1-weighted spin-echo MR ("black holes") with MS, we studied...
It has been shown that proinflammatory and antiinflammatory cytokines correlate with disease activity in multiple sclerosis (MS). To establish whether such correlations depend on the stage, we assessed a longitudinal fashion expression of interleukin (IL)-12 (p40 p35), tumor necrosis factor-α, interferon-γ, IL-10 mRNA by competitive polymerase chain reaction unstimulated peripheral blood mononuclear cells relapsing–remitting (RR) secondary progressive (SP) MS patients, relation to monthly...
We report the results of a randomized, double-blind, placebo-controlled exploratory trial chimeric monoclonal anti-CD4 antibody cM-T412 in 71 patients suffering from active relapsing-remitting and secondary progressive multiple sclerosis. Infusion produced frequent but usually minor side effects resulted long-lasting reduction circulating CD4-positive T cells. There was no significant effect on primary measure efficacy, number lesions monthly gadolinium-enhanced MRI over 9 months. Further...
<h3>Background</h3> Recent studies using colour-coded Doppler sonography showed that chronic impaired venous drainage from the central nervous system is almost exclusively found in multiple sclerosis (MS) patients. This study aimed to investigate intracranial and extracranial anatomy intracerebral flow profile patients with MS healthy controls magnetic resonance venography (MRV). <h3>Methods</h3> Twenty definite 20 age- gender-matched were examined. MR imaging was performed on a whole-body...
It has been suggested that natalizumab-associated progressive multifocal leukoencephalopathy may be prevented by structured interruptions of treatment. Evidence supporting such a drug holiday is not yet available. Here we present initial observations in 10 multiple sclerosis patients who were stringently monitored up to 6 months after discontinuation the infusions. Cumulatively, combination clinical relapse and new and/or enhanced lesions on magnetic resonance imaging had occurred 7...
<h3>Objective</h3> To investigate the MRI manifestation pattern of asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS). <h3>Methods</h3> 18 MS PML lesions on were included. In 6 patients, identified prospectively and 12 retrospectively. sequences analysed for lesion distribution, appearance, grey matter/white matter involvement possible signs inflammation. Lesion probability maps created to demonstrate distribution...
Fingolimod is an oral sphingosine 1-phosphate receptor modulator that prevents recirculation of lymphocyte subsets from lymph nodes. It decreases the number relapses, slows progression disability, and improves MRI endpoints in patients with relapsing-remitting multiple sclerosis (RRMS).1 Infrequent but specific side effects are bradycardia, leukopenia, macular edema. ### Case report. In November 2010, a 23-year-old woman RRMS since September 2007 started fingolimod 0.5 mg per day setting...
To evaluate the accuracy of recently proposed diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS).We enrolled 42 patients hindbrain punctate and/or linear enhancements (<3 mm in diameter) and tested CLIPPERS criteria.After a median follow-up 50 months (IQR 25-82), 13 out were CLIPPERS-mimics: systemic central nervous system lymphomas (n=7), primary angiitis (n=4) autoimmune gliopathies (n=2). The sensitivity...
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count ⩾10 cells/µL (starting 24 weeks after previous dose, repeated 4-weekly). Median interval until re-dosing or last 34 [30–38] weeks. No clinical relapses were reported and a minority showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable...
To determine whether natalizumab efficacy is maintained when switching to personalized extended interval dosing based on individual trough concentrations in patients with relapsing-remitting multiple sclerosis (RRMS).This was a prospective multicenter single-arm trial 1 year follow-up and 1-year extension phase. Participants were adult persons RRMS treated without disease activity the prior enrollment. The treatment longitudinal concentrations. Patients received 3 monthly MRI scans, relapse...
CD4(pos) TH1 T cells are considered to play a central role in number of human autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis. Experimental treatment protocols aimed at selectively eliminating thus far have yielded disappointing clinical results. Here we analyzed phenotype function circulating sclerosis patients treated with the chimeric CD4 mAb cM-T412 randomized, double-blind, placebo-controlled, magnetic resonance imaging-monitored phase II trial. Treatment...
Given the expansion of options for treatment relapsing multiple sclerosis, this review outlines framework developing a strategy, with consideration when to switch or discontinue therapies, and comprehensive elaboration mechanisms action, efficacy, safety considerations each therapeutic classes.The armamentarium immunotherapies has grown rapidly, encompass 19 US Food Drug Administration (FDA)-approved available in 2021, which are addressed review. The coronavirus pandemic that began 2020...
Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension intervals.
Background Natalizumab is a highly effective drug for patients with relapsing-remitting multiple sclerosis (MS). A disadvantage of this treatment the risk progressive multifocal leukoencephalopathy in who are seropositive John Cunningham virus (JCV). JCV seroconversion rates increase under natalizumab compared non-natalizumab using controls. The aim study was to assess whether lower trough concentrations associated reduced higher concentrations. Methods Two overlapping cohorts treated...
This cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.